HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri

被引:18
作者
Beskow, AH [1 ]
Moberg, M [1 ]
Gyllensten, UB [1 ]
机构
[1] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden
关键词
HLA; human papillomavirus; viral load; cervical carcinoma;
D O I
10.1002/ijc.21204
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human papillomavirus (HPV) infection is the most important risk factor for development of cervical carcinoma. Carriers of certain HLA class H alleles, e.g., DRBl*1501 and DQB1*0602, are more prone to HPV 16 infection and cervical carcinoma, whereas other alleles, e.g., DRB1*1301 and DQB1*0603, render carriers less susceptible to the disease. In our study comprising 484 cases and 601 controls, we examine the effect of HLA class II alleles on viral load of the oncogenic types HPV 18/45 and HPV 31 and risk of developing cervical carcinoma in situ. We find that carriers of the commonly reported protective DRBl*1301 and DQB1*0603 alleles have lower HPV 18/45 load compared to noncarriers and a lower risk of developing HPV 18/45-positive cervical carcinoma. This provides further evidence that the HLA class II-mediated immune response to HPV is important for controlling viral load and outcome of an infection. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:510 / 514
页数:5
相关论文
共 43 条
[21]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368
[22]   Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay [J].
Josefsson, A ;
Livak, K ;
Gyllensten, U .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :490-496
[23]   Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study [J].
Josefsson, AM ;
Magnusson, PKE ;
Ylitalo, N ;
Sorensen, P ;
Qwarforth-Tubbin, P ;
Andersen, PK ;
Melbye, M ;
Adami, HO ;
Gyllensten, UB .
LANCET, 2000, 355 (9222) :2189-2193
[24]   A controlled trial of a human papillomavirus type 16 vaccine [J].
Koutsky, LA ;
Ault, KA ;
Wheeler, CM ;
Brown, DR ;
Barr, E ;
Alvarez, FB ;
Chiacchierini, LM ;
Jansen, KU .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651
[25]   HLA and susceptibility to cervical neoplasia [J].
Krul, EJT ;
Schipper, RF ;
Schrueder, GMT ;
Fleuren, GJ ;
Kenter, GG ;
Melief, CJM .
HUMAN IMMUNOLOGY, 1999, 60 (04) :337-342
[26]   Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ [J].
Moberg, M ;
Gustavsson, I ;
Gyllensten, U .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (05) :854-859
[27]   Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer [J].
Moberg, M ;
Gustavsson, I ;
Gyllensten, U .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (07) :3221-3228
[28]   Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population [J].
Montoya, L ;
Saiz, I ;
Rey, G ;
Vela, F ;
Clerici-Larradet, N .
EUROPEAN JOURNAL OF IMMUNOGENETICS, 1998, 25 (05) :329-337
[29]   Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens [J].
Nakagawa, M ;
Stites, DP ;
Patel, S ;
Farhat, S ;
Scott, M ;
Hills, NK ;
Palefsky, JM ;
Moscicki, AB .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02) :595-598
[30]  
Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt